# KEYNOTE-789 (NCT03515837)

> Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: TKI-resistant EGFR-mutant metastatic nonsquamous non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03515837
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-small Cell Lung Cancer
- Interventions: pembrolizumab; pemetrexed; carboplatin; cisplatin; saline solution
- Enrollment: 492
- Primary outcome: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on KEYNOTE-789 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 40
- Podcasts: 27
- YouTube: 19

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-789-nct03515837

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03515837", "email": "<work email>"}; the inbox owner confirms by the emailed link.